About the PMPRB

The PMPRB protects and informs Canadians by ensuring that the prices of patented medicines sold in Canada are not excessive and by reporting on pharmaceutical trends.

CompassRx 3

CompassRx 2015-2016

After several years of low growth, drug costs in Canada’s public drug plans rose by 12% in 2015-16.

Discover what is driving this change…

Now available: Public submissions

Feedback submitted during Phase 1 of the Rethinking the Guidelines consultation initiative is now available.

Find out more…

NPDUIS Market Intelligence Report

The sales and use of biologic anti-inflammatory drugs are higher in Canada than in most comparable international markets. Despite the availability of lower-cost treatments, the majority of Canadian patients continue to use the drugs with the highest treatment costs: Remicade, Humira and Enbrel.

Find out more…

Meds Entry Report, 2015

High-price specialty drugs are increasingly dominating the new drug landscape in Canada and internationally. Results from this latest NPDUIS study also show the timing and number of new drugs launched in Canada to be on par with other countries.

Find out more…

Strategic Plan 2015-2018

PMPRB Strategic Plan – 2015-2018

The PMPRB’s three-year Strategic Plan includes four new strategic objectives, a reinvigorated mission statement, and a vision as to how the organization can work with partners and stakeholders in advancing the common goal of a sustainable health system.

Find out more…

I am a/an...

Consumer

Patentee

Other Stakeholder

Features

Annual Report

PMPRB quarterly NEWSletter

Analytical Studies

Date modified: